ArticleJournal of cardiothoracic surgery2026
Neither tranexamic acid nor ulinastatin affects the activated clotting time values in healthy volunteers and heparinized cardiovascular surgery patients.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundTo investigate the effects of tranexamic acid (TXA) and ulinastatin (UTI) on activated clotting time (ACT) of healthy volunteers and cardiovascular surgical patients in the in-vitro study.
methodsBlood samples of ten healthy volunteers adding unfractionated heparin (UFH) concentrations of 0.5 IU/mL, 1.0 IU/mL, and 2.0 IU/mL. Then mixed with TXA concentrations of 10 µg/mL, 20 µg/mL, 50 µg/mL, 100 µg/mL, and 200 µg/mL, or mixed with UTI concentrations of 100 U/mL, 200 U/mL, 1,000 U/mL, 5,000 U/mL, and 10,000 U/mL. The blood samples from patients underwent different types of heparinized cardiovascular surgery (non-cardiac arterial procedures [NCAP], off-pump coronary artery bypass grafting [OPCAB], and cardiopulmonary bypass cardiac surgery [CPB-CS]) were directly added with different concentrations of TXA or UTI. ACT were measured after adding UFH, UFH mixed TXA, or UFH mixed UTI.
resultsThere was no statistical difference observed in ACT values among different concentrations of TXA in heparinized blood samples from healthy volunteers and patients underwent different types of cardiovascular surgery (HUFH0.5−TXA=2.899, P = 0.716; HUFH1.0−TXA=0.905, P = 0.970; HUFH2.0−TXA=5.630, P = 0.344; HNCAP−TXA=2.331, P = 0.802; HOPCAB−TXA=2.983, P = 0.703; HCPB−TXA=0.502, P = 0.992). There was also no statistical difference in ACT values among different concentrations of UTI in heparinized blood samples from healthy volunteers and patients underwent cardiovascular surgery (HUFH0.5−UTI=2.564, P = 0.767; HUFH1.0−UTI=8.188, P = 0.146; HUFH2.0−UTI=1.559, P = 0.906; HNCAP−UTI=2.362, P = 0.797; HOPCAB−UTI=1.819, P = 0.874; HCPB−UTI=0.386, P = 0.996).
conclusionsThe current in-vitro study indicated that the presence of concentrations of TXA and UTI did not exert a significant influence on ACT during healthy volunteers and heparinized cardiovascular surgical patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.